{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-083719","form_type":"8-K","ticker":"ADIL","cik":"0001513525","company_name":"ADIAL PHARMACEUTICALS, INC.","filed_at":"2025-09-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.180486+00:00","generated_at":"2026-05-17T08:29:21.212785+00:00","sec_items":["3.01","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Adial Pharmaceuticals granted 180-day Nasdaq extension to meet $1.00 bid price rule by March 2, 2026","bullets":["Received Nasdaq extension until March 2, 2026 to regain compliance with minimum $1.00 bid price requirement.","Initial 180-day compliance period ended September 1, 2025; extension granted due to meeting other listing criteria.","Company must maintain closing bid ≥ $1.00 for 10 consecutive business days before deadline.","If necessary, company will consider a reverse stock split to cure deficiency.","No immediate effect on trading; stock continues on Nasdaq Capital Market under symbol ADIL."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-083719","json":"https://secwatch.observer/filing/0001213900-25-083719.json","markdown":"https://secwatch.observer/filing/0001213900-25-083719.md","text":"https://secwatch.observer/filing/0001213900-25-083719.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1513525/000121390025083719/0001213900-25-083719-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1513525/000121390025083719/ea0255741-8k_adial.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T08:29:21.212785+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6aad643a378cd6caf030055f948b4c4e8a48e234","claim":"ADIAL PHARMACEUTICALS, INC. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"September 2, 2025, Adial Pharmaceuticals, Inc. (the “Company”) received a letter (the “September 2025 Nasdaq Letter”) from The Nasdaq Stock Market (“Nasdaq”) stating that the Company is eligible for an additional 180 calendar days, or until March 2, 2026, to regain compliance with Nasdaq’s requirement to maintain a minimum closing bid price of $1.00 per share as required by Nasdaq Listing Rule 5550(a)(2) (the “Rule”) for continued listing on Nasdaq (the “Minimum Bid Price Requirement”), following the expiration of the initial 180 calendar day period granted to the Company by Nasdaq to regain c","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390025083719/0001213900-25-083719-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"extension granted"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}